Non-invasive Glucose Monitoring
GWave is the world's first non-invasive glucometer, which offers a disruptive solution utilizing radio frequency (RF) waves to continuously measure glucose levels in the blood.
The revolutionary concept was conceived by GWave’s CTO and Co-founder, Dr. Geri Waintraub, when he accidently spilled a cup of tea on an RF device during routine experimentation for an RF research initiative.
He immediately noticed that the sugar in the tea caused the dramatic reaction on the system’s monitors.
Following the serendipitous spill, Dr. Waintraub began formulating ideas about the enormous applications the technology could have toward helping hundreds of millions of people with diabetes worldwide.
GWave’s technology was developed into a prototype that yielded a successful POC with astonishing results that meet the FDA guidelines.
Utilizes RF Wave technology that monitors glucose levels in the blood continuously and in real-time. User safety is our foremost priority, using significantly less radiation than a smartphone.
GWave’s sensors are developed with propriety AI algorithms that enables GWave to be cost-efficient, compact, and capable of delivering impeccably accurate measurements.
Our device seamlessly connects to Bluetooth and smartphones, creating a painless, straightforward and pleasant user experience.
Users can track their glucose readings as frequently and repeatedly as needed.
The built-in automated alarm feature is a key benefit to ensure proper notification to the user of fluctuation in glucose levels.
Our cloud securely stores all the user’s measurement data, and can deliver important information to caretakers and medical professionals. Our software is safe, secure, and reliable.
Our device’s accuracy is over 95% when compared to an off-theshelf handheld finger-prick device.
With GWave’s innovative technology, glucose is monitored in the blood and not in the interstitial fluid. Monitoring the blood itself yields efficient and incredibly accurate results.
HAGAR GWave Awarded FDA Breakthrough Device Designation
HAGAR GWave Awarded FDA Breakthrough Device Designation Expediting Development of GWave technology that may potentially improve the health and quality of life for millions of diabetes patients
HAGAR Secures $11.7M Series B Funding to Advance Non-Invasive Blood Glucose Monitoring Technology
GWave 2.0 delivers accurate, affordable, and accessible continuous monitoring and testing for blood glucose, improving the quality of life for the global diabetes population
Hagar Noninvasive Glucometer Announces $4.4m Series A for World’s First Wearable, Non-Invasive Glucose Monitoring Device
GWave Technology to Improve Quality of Life for Millions of Diabetes Worldwide by Eliminating the Need for Painful, Inconvenient Finger Pricking Tests
In the Press
General Guy Zur
General Zur joined the IDF in 1983 and served in the military until 2016 in a variety of positions retiring with the rank of Major General.
Dr. Gerry Waintraub
Dr. Waintraub, holds a PhD. in physics and electronics and has over 30 years’ experience in developing electronic systems for multi-market segments
Maor’s creativity and expert organizational skills has attributed to her ability to multi-task, run variety of administrative needs and seamlessly bring together multiple initiatives
Dr. Irl Hirsch
Medical Advisor, US
Dr. Hirsch received his medical degree from the University of Missouri School of Medicine in 1984. He completed residency training in internal medicine at the University of Miami
Alexander Fleming, M.D.
Medical and Regulatory Advisor, US
Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices.
Dr. Moshe Rubin
Medical Advisor, Israel
Dr. Moshe Rubin is an Associate Professor of Clinical Medicine at Weill-Cornell Medical College and a Physician Leader with extensive administrative and medical device industry experience.